Myocardial Gene Expression Profiling to Predict and Identify Cardiac Allograft Acute Cellular Rejection: The GET-Study

Diane Bodez1,2,3,4, Hakim Hocini2,3,5, Nicolas Tchitchek6,7, Pascaline Tisserand2,3,5, Nicole Benhaiem6, Caroline Barau2,3,9, Mounira Kharoubi1,10, Aziz Guellich1,2,3,4,10, Soulef Guendouz1,2,4,10, Costin Radu11, Jean-Paul Couetil2,3,11, Bijan Ghaleh2,3,9, Jean-Luc Dubois-Rande1,2,3,4, Emmanuel Teiger1,2,3,4, Luc Hittinger1,2,3,4, Yves Levy2,3,5,12*, Thibaud Damy1,2,3,4,10**

1 AP-HP, Department of Cardiology, Henri Mondor Teaching Hospital, Créteil, France, 2 School of Medicine, Paris-Est-Créteil University (UPEC), Créteil, France, 3 IMRB INSERM U955, Paris-Est-Créteil University (UPEC), Créteil F-94000, France, 4 DHU ATVB, Henri Mondor Teaching Hospital, Créteil, France, 5 Vaccine Research Institute (VRI), Henri Mondor Teaching Hospital, Créteil, France, 6 CEA, DSV/IMETI, Immunology of viral infections and autoimmune diseases research unit, Fontenay-aux-Roses, France, 7 UMR1184, IDMIT infrastructure, Fontenay-aux-Roses, France, 8 AP-HP, Department of Pathology, Henri Mondor Teaching Hospital, Créteil, France, 9 AP-HP, Platform of Biological Resources, Henri Mondor Teaching Hospital, Créteil, France, 10 GRC Amyloid Research Institute, Henri Mondor Teaching Hospital, Créteil, France, 11 AP-HP, Department of Cardiac Surgery, Henri Mondor Teaching Hospital, Créteil, France, 12 AP-HP, Clinical Immunology, Henri Mondor Teaching Hospital, Créteil, France

* These authors contributed equally to this work.
† yves.levy@aphp.fr (YL); thibaud.damy@aphp.fr (TD)

Abstract

Aims

Serial invasive endomyocardial biopsies (EMB) remain the gold standard for acute cellular rejection (ACR) diagnosis. However histological grading has several limitations. We aimed to explore the value of myocardial Gene Expression Profiling (GEP) for diagnosing and identifying predictive biomarkers of ACR.

Methods

A case-control study nested within a retrospective heart transplant patients cohort included 126 patients with median (IQR) age 50 (41–57) years and 111 (88%) males. Among 1157 EMB performed, 467 were eligible (i.e, corresponding to either ISHLT grade 0 or ≥3A), among which 36 were selected for GEP according to the grading: 0 (CISHLT, n = 13); rejection ≥3A (RISHLT, n = 13); 0 one month before ACR (BRISHLT, n = 10).

Results

We found 294 genes differentially expressed between CISHLT and RISHLT, mainly involved in immune activation, and inflammation. Hierarchical clustering showed a clear segregation of CISHLT and RISHLT groups and heterogeneity of GEP within RISHLT. All EMB presented immune activation, but some RISHLT EMB were strongly subject to inflammation, whereas others, closer to CISHLT, were characterized by structural modifications with lower
inflammation level. We identified 15 probes significantly different between BR\text{ISHLT} and C\text{ISHLT}, including the gene of the muscular protein TTN. This result suggests that structural alterations precede inflammation in ACR. Linear Discriminant Analysis based on these 15 probes was able to identify the histological status of every 36 samples.

**Conclusion**

Myocardial GEP is a helpful method to accurately diagnose ACR, and predicts rejection one month before its histological occurrence. These results should be considered in cardiac allograft recipients’ care.

**Introduction**

Cardiac transplantation is the ultimate therapy of end-stage heart failure. Notable advances in immunosuppression allowed significant reduction of both incident and treated acute rejections. However, these therapies are not devoid of severe drawbacks[1] while the incidence of graft rejection remains higher than 25% during the first year post-transplantation with an increased morbidity and mortality.[2] Graft failure and allograft vasculopathy that are related to immune injury, are also main causes of death. Thus, management of allograft rejection is a major clinical concern in the care of heart transplant recipients. Serial endomyocardial biopsies (EMB) for histological examination remain the gold-standard in diagnosing and monitoring acute rejection, based on the 1990 International Society of Heart and Lung Transplantation (ISHLT) classification, revised in 2004.[3] EMB is an invasive procedure, with potential risk of serious complications such as right ventricular perforation or tricuspid regurgitation, and high cost. Moreover, this histopathological assessment is subject to sampling errors and inter-observer variability, especially for EMB with severe rejection. Thus, the ISHLT grading might be not optimal for clinical decisions.[4] Hence, alternative methods are needed for recipients’ management. A number of approaches have been already outlined with a critical focus on using DNA microarray to characterize the gene expression profile (GEP) associated with the ACR.[5–9] Nevertheless, none of these approaches have demonstrated sufficient reliability and feasibility in clinical practice to fully supersede the EMB, whereas interest has been described for risk stratification in heart transplantation[10] or for differential diagnosis improvement in myocardial diseases.[11] In the current study, we investigated GEP of EMB, to find out a genomic signature that could be used for characterizing ACR and predicting its occurrence one month before the histopathological diagnosis.

**Methods**

**Patient population**

The retrospective cohort of cardiac allograft recipients at Henri Mondor teaching hospital (Créteil, France) between 2003 and 2012 included 126 patients. They received immunosuppressive induction with polyclonal anti-lymphocyte globulin or interleukine-2 receptor antagonist (basiliximab), and the maintenance immunosuppression usually associated prednisone, a calcineurin inhibitor and a cell cycle inhibitor. In some cases, an mTOR inhibitor was used, instead or in addition to calcineurin- or cell cycle inhibitor, or alone with prednisone. Episodes of ACR ≥ grade 2 (ISHLT 1990) were treated with intravenous pulse steroids, change in oral
maintenance therapy if needed, and anti-lymphocytes agents or intravenous immunoglobulin in specific cases.

Sample collection
For routine ACR surveillance, EMB were systematically performed during the follow-up period: monthly the first and quarterly the second year post-transplantation (except in the case of contra-indication, with extra EMB in case of rejection suspicion). Among the 126 patients that underwent cardiac allograft during this period, 21 did not undergo any biopsy because of hemodynamic instability and early death. Among the 105 remaining patients, a total of 1157 biopsies were performed. For each biopsy, 2 to 4 samples were obtained from the right ventricle for ACR histological grading by an experienced cardiac pathologist (NL), according to the 1990 ISHLT criteria since ISHLT guidelines were revised in 2004 during the study period.

Study design
We conducted a nested case-control study of intragraft gene expression profiles within our cohort of 105 biopsied patients (Fig 1). Study groups were defined as followed: control group (C\textsubscript{ISHLT}): grade 0; rejection group (R\textsubscript{ISHLT}): grade \geq 3A (i.e. \geq 2R ISHLT 2004); before rejection group (BR\textsubscript{ISHLT}): grade 0 biopsies followed by a grade \geq 2 rejection on the next monthly biopsy. To minimize confounders, control samples were obtained from patients without any episode of rejection in the first year following transplantation. For homogeneity reasons, EMB from 1 to 12 months post-transplantation were screened for inclusion. All R\textsubscript{ISHLT} and BR\textsubscript{ISHLT} samples of sufficient RNA quality for transcriptome analysis were included (n = 13 and n = 10, respectively). Biopsies of C\textsubscript{ISHLT} group (n = 13) were matched to other biopsies’ groups for donor’s and recipient’s gender and age, primary cardiac diagnosis, date of transplantation, and time of biopsy from transplantation. Immunosuppressive treatment and all rejection episodes were recorded. The study complied with the Declaration of Helsinki and was approved by the local ethic committee (CPP Ile de France VI). All survival subjects for whom biopsies were used in this study provided their informed written consent. None of the transplant donors were from a vulnerable population.

![Flow chart of EMB collection from heart transplantation to inclusion in the GET-study.](doi:10.1371/journal.pone.0167213.g001)
RNA isolation and microarray sample preparation

Frozen EMB were immediately immersed into RLT-beta-mercaptoethanol (βME, 1/100) lysis buffer (Qiagen, Courtaboeuf Cedex, France). Samples were then disrupted and homogenized using a TissueLyser LT (Qiagen, Courtaboeuf Cedex, France). RNA was purified with Qiagen RNeasy Micro Kit and quantified using a ND-8000 spectrophotometer (NanoDrop Technologies, Fisher Scientific, Illkirch Cedex, France) before being checked for integrity on a 2100 BioAnalyzer (Agilent Technologies, Massy Cedex, France). cDNA was synthesized and biotin-labeled cRNA was generated by an in vitro transcription reaction using Ambion Illumina TotalPrep RNA Amplification Kits (Applied Biosystem/Ambion, Saint-Aubin, France). Labeled cRNA were hybridized on Illumina Human HT-12V4 BeadChips that targets 47323 probes corresponding to 34694 genes. All steps were done following the manufacturers’ protocols. Microarray row data are available on the EBI-ArrayExpress database under the accession number E-MTAB-5136.

Statistical analysis

Continuous variables are described as median (interquartile range) and categorical variables in percent (%). Comparisons between groups were made using the Mann-Whitney or the Kruskal-Wallis test for continuous data, and the $\chi^2$ test for categorical variables. Statistical analyses were done with the use of Prism 6.05 Software (GraphPad Software Inc, La Jolla, CA). P-values $\leq 0.05$ were considered significant. The inter-observation variability for histological analysis was assessed by calculating the weighted kappa coefficient between two blind readings. Microarray data analyses were performed blind to clinical data using R software version 3.0.1. Raw data were quantile normalized via the Limma package[12] first background subtraction, then log2 transformation and quantile normalization were applied. A gene was considered as differentially expressed 1) when a comparison between two groups yielded a P-value $\leq 0.05$ in the student parametric test and 2) a variation of at least 1.3-fold was observed. Fold-change was raised to 1.5 for the comparison between Rejection and Control groups in order to restrict the number of probes differentially expressed. Hierarchical clustering was performed on scaled gene expression based on the Euclidean distance and the Ward’s linkage method. Canonical pathways and biological functions associated with differentially expressed genes were identified using Ingenuity Pathway Analysis software (IPA®, Qiagen, Redwood City, www.qiagen.com/ingenuity). Linear Discriminant Analysis (LDA) was further performed using the ‘MASS’ package with the intention of predicting EMB histological features from their individual gene expression levels.

Results

Patient characteristics

According to inclusion criteria, 467 EMB were eligible (i.e. corresponding to either ACR grade 0 or $\geq 3A$ between 1 and 12 months post-transplantation). Among them (Fig 1), 429 showed no evidence of ACR (grade 0) and 38 showed rejection $\geq$ grade 3A. In Rishlt and Brishlt groups, all samples reaching quality criteria for microarray analysis were included. Samples of the Cishlt group were matched to those previously included in the other groups. Thirty-six biopsies belonging to 30 patients were studied (group Cishlt, $n = 13$; group Risht, $n = 13$; group Brishlt, $n = 10$). Weighted kappa coefficient evaluating the agreement between two histological readings of these biopsies was 0.828. The 30 patients included for GEP analysis were not different from the 75 biopsied patients without GEP (Table 1). Among the 30 patients, 22 were male (73.3%). Age at the time of EMB was 52.1(34.5;57.2) years. Time between
transplantation and EMB was 4.1(1.5;5.8) months and median EMB conservation time before RNA purification was 52.4(21.4;79.2) months. Samples of the BRISHLT group were collected 34 (29;35) days before the episode of rejection. RIN (RNA Integrity Number) was 6.2(5.8;6.5).

Characteristics of the 36 biopsies and relative patients are presented in Table 2. Comparisons of 3 groups’ characteristics are given in Table 3. There were no significant differences between the 3 groups with the exception of proportion of mycophenolate mofetil-treated patients.

Distinctive gene expression profiles between rejection and control groups

We found 341 probes corresponding to 294 annotated genes differentially expressed between CISHLT and RISHLT. Most differentially expressed genes were Chemokines CXCL9 and CCL5, and Lymphotoxin Beta (LTB), all upregulated in 5.3- to 7.3-fold in the RISHLT group (Table 4). Considering all, genes differentially expressed between CISHLT and RISHLT groups basically involved in antigen presentation (HLA-DR, HLA-DM, HLA-DP, TAP1), lymphocytes recruitment (CXCL9, CCL5, CCL8, CD44), T-cell activation (LTB, CD247, CD86) and Interferon responses (CXCL9, STAT1, IRF8, IRF1), as depicted in Fig 2A. The antigen presentation pathway was particularly represented with 15 genes differentially expressed among the 36 genes known to be part of this pathway (Figs 2A and 3).

We used hierarchical clustering to assess the ability of the 341 probes to distinguish control and rejection samples. As shown in Fig 2B, samples clustered clearly into 2 main clusters (❶, ❷) corresponding to CISHLT and RISHLT samples, respectively. One CISHLT sample clustered with RISHLT samples; it has been considered according to its gene expression profile close to RISHLT samples rather than its pathological grading, in the further GEP analyses.

Heterogeneity of gene expression profiles among rejection samples

Fig 2B shows that samples of CISHLT and RISHLT clustered in sub-clusters rather than into single branches, indicating heterogeneity of cardiac gene expression within each group despite an homogeneous histological classification of CISHLT (grade 0) and RISHLT (grade 3A). Comparison between the most extreme gene expression profiles, cluster Control ❶ and sub-cluster Rejection ❷, showed that 548 annotated genes were differentially expressed, mainly involved in antigen presentation, immune activation and inflammatory response. Interestingly, the same pathways were associated with the 213 annotated genes differentially expressed between sub-clusters Rejection ❷ and ❶. Besides, only 35 annotated genes differentiated Cluster Control ❶ to sub-cluster Rejection ❷, making this intermediate Rejection cluster (❸) closer to the Control cluster (❶) than to the acute inflammatory Rejection cluster (❹). Fig 2C shows the

### Table 1. Baseline characteristics of the patients with EMB according to selection for GEP analysis.

| Variables/Heart Transplant patients | Overall EMB patients | EMB patients without GEP | EMB patients with GEP | P-value |
|-------------------------------------|----------------------|--------------------------|----------------------|---------|
| n                                   | 105                  | 75                       | 30                   |         |
| Recipient age, years                | 50 (39;57)           | 50 (40;57)               | 50 (40;56)           | .74     |
| Recipient sex, male, n(%)           | 84 (80)              | 61 (81)                  | 22 (73)              | .60     |
| Primary cardiac diagnosis           |                      |                          |                      |         |
| • Idiopathic dilated cardiomyopathy | 41 (39)              | 25 (33)                  | 16 (53)              | .50     |
| • Ischemic cardiomyopathy           | 36 (34)              | 28 (37)                  | 8 (27)               |         |
| • Others                            | 28 (27)              | 22 (29)                  | 6 (20)               |         |

EMB: endomyocardial biopsy; GEP: gene expression profiling
doi:10.1371/journal.pone.0167213.t001
| Sample | ISHLT     | Patient age (y) | Donor age (y) | Recipient gender | Donor gender | Transplant status | Time from Tx (months) | Prednisone (mg/d) | Cyclosporine (mg/d) | MMF (g/d) | Tacrolimus (mg/d) | Everolimus (mg/d) | Sirolimus (mg/d) | Induction |
|--------|-----------|----------------|-------------|-----------------|-------------|------------------|---------------------|-------------------|-------------------|-----------|------------------|-------------------|-----------------|-----------|
| 1      | 0         | 23             | 33          | F               | F           | BR               | 5.1                 | 8                 | 250               | -         | -                | -                 | -               | ATG       |
| 2      | 0         | 31             | 16          | M               | M           | C                | 2.2                 | 25                | 475               | 2.5       | -                | -                 | -               | ATG       |
| 3      | 0         | 50             | 54          | M               | M           | C                | 8.1                 | 5                 | -                 | 1.5       | -                | -                 | -               | ATG       |
| 4      | 0         | 31             | 16          | M               | M           | C                | 5.6                 | 10                | 425               | 1.5       | -                | -                 | -               | ATG       |
| 5      | 0         | 32             | 43          | M               | F           | BR               | 5.0                 | 20                | 350               | 2.0       | -                | -                 | -               | ATG       |
| 6      | 3A        | 53             | 31          | M               | M           | R                | 1.4                 | 25                | 275               | 2.25      | -                | -                 | -               | ATG       |
| 7      | 3A        | 58             | 16          | M               | M           | R                | 4.6                 | 25                | -                 | 3.0       | 5                | -                 | -               | ATG       |
| 8      | 3A        | 33             | 43          | F               | F           | R                | 1.3                 | 30                | 300               | 3.0       | -                | -                 | -               | ATG       |
| 9      | 0         | 59             | 21          | M               | M           | BR               | 1.0                 | 30                | -                 | -         | 1                | -                 | -               | ATG       |
| 10     | 3A        | 50             | 20          | M               | F           | R                | 1.5                 | 20                | 300               | 1.0       | -                | -                 | -               | ATG       |
| 11     | 3A        | 59             | 21          | M               | M           | R                | 4.2                 | 10                | -                 | 1.0       | 6                | 1.5               | -               | ATG       |
| 12     | 3A        | 42             | 59          | M               | F           | R                | 6.9                 | 5                 | -                 | 1.0       | -                | 1                 | -               | ATG       |
| 13     | 0         | 64             | 60          | M               | F           | BR               | 10.9                | 10                | -                 | -         | 7                | -                 | -               | ATG       |
| 14     | 3A        | 64             | 60          | M               | F           | R                | 11.7                | 5                 | -                 | -         | 7                | -                 | -               | ATG       |
| 15     | 3A        | 34             | 58          | M               | F           | R                | 1.0                 | 25                | -                 | 2.0       | 4                | -                 | -               | IL2R-I   |
| 16     | 0         | 53             | 25          | M               | M           | C                | 3.9                 | 20                | -                 | 1.5       | 5                | -                 | -               | IL2R-I   |
| 17     | 0         | 57             | 56          | M               | F           | C                | 2.0                 | 15                | -                 | 2.0       | 8                | -                 | -               | IL2R-I   |
| 18     | 0         | 61             | 61          | F               | F           | BR               | 8.2                 | 15                | -                 | 1.5       | 4                | -                 | -               | IL2R-I   |
| 19     | 3A        | 54             | 33          | M               | M           | R                | 1.1                 | 50                | -                 | 1.0       | 2                | -                 | -               | IL2R-I   |
| 20     | 3A        | 34             | 58          | M               | F           | R                | 5.3                 | 15                | 0.72              | 2         | -                | -                 | -               | IL2R-I   |
| 21     | 0         | 57             | 62          | M               | M           | C                | 2.1                 | 20                | -                 | 3.0       | 2                | -                 | -               | IL2R-I   |
| 22     | 0         | 54             | 33          | M               | M           | BR               | 6.0                 | 20                | -                 | 5         | 2                | -                 | -               | IL2R-I   |
| 23     | 0         | 53             | 53          | M               | M           | BR               | 5.5                 | 15                | 250               | 3.0       | -                | -                 | -               | ATG       |
| 24     | 0         | 35             | 42          | M               | M           | C                | 2.1                 | 35                | -                 | 2.0       | 5                | -                 | -               | ATG       |
| 25     | 0         | 24             | 50          | F               | F           | C                | 3.4                 | 25                | 150               | 1.0       | -                | -                 | -               | ATG       |
| 26     | 0         | 24             | 50          | F               | F           | C                | 6.2                 | 15                | 150               | 1.0       | -                | -                 | -               | ATG       |
| 27     | 3A        | 44             | 21          | M               | M           | R                | 5.1                 | 45                | 375               | 3.0       | -                | -                 | -               | IL2R-I   |
| 28     | 3A        | 51             | 53          | M               | F           | R                | 7.7                 | 10                | -                 | 3.0       | -                | 1                 | -               | ATG       |
| 29     | 0         | 49             | 20          | F               | F           | BR               | 1.4                 | 25                | 200               | 2.5       | -                | -                 | -               | ATG       |
| 30     | 0         | 39             | 51          | M               | M           | BR               | 0.2                 | 25                | -                 | 1.0       | 6                | -                 | -               | IL2R-I   |
| 31     | 0         | 51             | 17          | F               | M           | C                | 1.3                 | 65                | 350               | 2.0       | -                | -                 | -               | ATG       |
| 32     | 0         | 59             | 46          | F               | F           | BR               | 1.2                 | 40                | 150               | 1.5       | -                | -                 | -               | ATG       |
| 33     | 0         | 57             | 18          | M               | M           | C                | 2.7                 | 25                | -                 | 1.0       | 8                | -                 | -               | ATG       |
| 34     | 3A        | 57             | 62          | F               | F           | R                | 8.2                 | 10                | 150               | 0.5       | -                | -                 | -               | ATG       |
| 35     | 0         | 61             | 52          | M               | F           | C                | 4.6                 | 15                | -                 | 2.0       | 16               | 4                 | -               | ATG       |
| 36     | 0         | 57             | 60          | M               | F           | C                | 3.7                 | 15                | -                 | 1.5       | 5                | -                 | -               | ATG       |

ATG: Anti-thymoglobulin; BR: before rejection (BR<sub>ISHLT</sub>); C Control (<sup>C</sup>ISHLT); EMB: endomyocardial biopsy; GEP: gene expression profile; F: female; ISHLT: International Society of Heart and Lung Transplantation; M: Male; MMF: mycophenolate mofetil; IL2R-I: IL2 receptor inhibitor; R: rejection (<sup>R</sup>ISHLT); Tx: transplantation

doi:10.1371/journal.pone.0167213.t002
### Table 3. Baseline characteristics of the EMB having GEP determine according to histological status.

| Variables/Groups                      | C<sub>ISHLT</sub> | R<sub>ISHLT</sub> | BR<sub>ISHLT</sub> | P-value |
|---------------------------------------|-------------------|-------------------|-------------------|---------|
| n                                     | 13                | 13                | 10                |         |
| Recipient age, years                  | 52 (31;57)        | 51 (38;58)        | 54 (37;60)        | 0.61    |
| Recipient sex, male, n(%)*            | 9 (82)            | 10 (83)           | 7 (70)            | 0.72    |
| Donor sex, male, n(%)*                | 7 (64)            | 5 (42)            | 4 (40)            | 0.47    |
| EMB conservation time, months         | 25.0 (8.2;73.5)   | 65.9 (36.6;80.1)  | 48.3 (24.9;83.0)  | 0.48    |
| Time from transplantation, months     | 3.4 (2.1;5.1)     | 4.6 (1.4;7.3)     | 5.1 (1.2;6.6)     | 0.93    |
| Immunosuppressive therapy at EMB time |                   |                   |                   |         |
| • Prednisone, n(%)                    | 13 (100.0)        | 13 (100.0)        | 10 (100.0)        | 1.00    |
| • Calcineurin inhibitor, n(%)         | 13 (100.0)        | 11 (84.6)         | 10 (100.0)        | 0.15    |
| • Mycophenolate mofetil, n(%)         | 13 (100.0)        | 12 (92.3)         | 6 (60.0)          | 0.02    |
| • mTOR inhibitor, n(%)                | 1 (7.7)           | 3 (23.1)          | 1 (10.0)          | 0.48    |
| Induction therapy, any, n(%)*         | 11 (100)          | 12 (100)          | 10 (100)          | 1.00    |
| • Anti-thymoglobulin, n(%) (vs Basiliximab) | 8 (72.7)      | 9 (75.0)          | 7 (70.0)          | 0.97    |

* Based on number of patient per group. ISHLT: International Society of Heart and Lung Transplantation; EMB: endomyocardial biopsy; other abbreviations as in Table 2

doi:10.1371/journal.pone.0167213.t003

### Table 4. Top list of differentially expressed genes between C<sub>ISHLT</sub> and R<sub>ISHLT</sub> groups.

| Gene symbol | Gene name                                  | Function                                      | FC  |
|-------------|--------------------------------------------|-----------------------------------------------|-----|
| 1           | CXCL9 Chemokine (C-X-C motif) ligand 9     | T-cell, chemokine                             | 7.3 |
| 2           | LTB Lymphotoxin bêta                       | Lymphoid response                             | 5.6 |
| 3           | CCL5 Chemokine (C-C Motif) Ligand 5 (= RANTES) | T-cell, chemokine                             | 5.3 |
| 4           | CD3D CD3 Delta Chain (CD3-TCR complex)    | T-cell                                        | 4.8 |
| 5           | LCP1 Plastin-2                             | Hematopoietic cell lineages                   | 4.5 |
| 6           | RAC2 Ras-related C3 botulinum toxin substrate 2 | Small signalling G protein                   | 4.3 |
| 7           | RARRES3 Retinoic acid receptor responder protein 3 | Cellular differentiation                 | 4.3 |
| 8           | CD8A Cluster of Differentiation 8A        | Cytotoxic T-cell                              | 4.1 |
| 9           | STAT1 Signal Transducer And Activator Of Transcription 1 | Interferon responses                        | 4.0 |
| 10          | ITGB2 Integrin bêta-2 (CD18)              | Cell adhesion, cell-surface signalling        | 3.6 |
| 11          | HCST Hematopoietic cell signal transducer | Hematopoietic cell                           | 3.5 |
| 12          | CTSC Cathepsin C                           | Serine proteases in immune cells              | 3.3 |
| 13          | CD52 CAMPATH-1 antigen                     | Mature lymphocytes, monocytes, dendritic cells | 3.3 |
| 14          | CD74 HLA-class II histocompatibility antigen, DR invariant chain | Antigen presentation                      | 3.3 |
| 15          | AIF1 Allograft inflammatory factor 1       | IFN gamma responses                           | 3.2 |
| 16          | HLA-DRA HLA-class II histocompatibility antigen, DR alpha chain | Antigen presentation                        | 3.1 |
| 17          | PLEK Pleckstrin                            | Haemostasis                                   | 3.1 |
| 18          | GZMA Granzyme A                            | Cytotoxicity                                  | 3.0 |
| 19          | VCAM1 Vascular cell adhesion protein 1, (= CD106) | Endothelial leucocytes adhesion             | 3.0 |
| 20          | THY1 Thymocyte antigen 1, (= CD90)         | Thymocytes, pro-thymocytes                    | 3.0 |

FC: Fold-change

doi:10.1371/journal.pone.0167213.t004
overlap of genes differentially expressed in the three comparisons. Twenty-two genes were thus identified to be specific of the sub-cluster intermediate Rejection (Table 5). Two genes were associated to the cardiovascular system (NPPA, NPPB), 3 to immune response (CD3D, CD8A, CD74), and 9 to the extra-cellular matrix (COL3A1, COL1A2, LUM, BGN, COL6A2, FBLN2, ECM1, APOD, BGN).

Gene expression signature one month before rejection

Comparison of GEP between C\textsubscript{ISHLT} and R\textsubscript{ISHLT} showed 15 differentially expressed probes, corresponding to 11 annotated genes (Table 6) of which fold-changes absolute values were higher than 1.3. Among them, MAL that is involved in T-cell signal transduction, TTN

Fig 2. Comparison of gene expression profiles between C\textsubscript{ISHLT} and R\textsubscript{ISHLT} groups. 2A (top). Top 20 canonical pathways significantly over-represented in R\textsubscript{ISHLT} compared to C\textsubscript{ISHLT} group, listed in the order of-log(p-value) of over-representation (the first pathway being the more significantly over-represented). Ratio indicates the number of genes differentially expressed related to the number of genes known to be part of the pathway. 2B (left bottom). Heatmap with hierarchical clustering for the 341 probes differentially expressed between C\textsubscript{ISHLT} and R\textsubscript{ISHLT} samples. Gene expressions row scaled. 2C (right bottom). Overlaps of differentially expressed genes between the three clusters Control (❶), intermediate Rejection (❸), and acute inflammatory Rejection (❹).

doi:10.1371/journal.pone.0167213.g002
involved in striated muscle contraction and PI16 that negatively regulate cell growth involved in cardiac muscle cell development and also plays a role in Treg functions. Based on the expression level of these 15 probes, hierarchical analysis was able to segregate samples into two main clusters corresponding to \( C_{\text{ISHLT}} \) and \( R_{\text{ISHLT}} \) groups, respectively (Fig 4).

Linear discriminant model to segregate C, BR and R samples

In order to estimate the ability of this 15 probes signature to segregate all the conditions, we performed a LDA based on the individual expression levels of 15 probes in each EMB. The analysis was able to discriminate clearly biopsies from each histological group (Fig 5). Moreover, LDA can identify \( R_{\text{ISHLT}} \) samples, meaning that a histological rejection episode can be predicted one month before its occurrence.

Discussion

In the current study we show first that GEP discriminates \( C_{\text{ISHLT}} \) and \( R_{\text{ISHLT}} \) EMB. Second, GEP analysis reveals a heterogeneous profile among the histological homogeneous group of \( R_{\text{ISHLT}} \) EMB, with a possible continuum from intermediate rejection characterized by heart structural modifications to acute inflammatory rejection features. Third, taking the opportunity to explore the GEP of EMB classified as grade 0, in a median of 34 days before rejection,
### Table 5. List of 22 genes exclusively differentially expressed between Control cluster \(\Theta\) and Intermediate Rejection sub-cluster \(\Theta\).

| Gene symbol | Gene name                          | Function                        | FC   |
|-------------|------------------------------------|---------------------------------|------|
| 1           | COL3A1 Collagen alpha-1(III) chain | Connective tissue               | 2.7  |
| 2           | COL1A2 Collagen alpha-2(I) chain   | Connective tissue               | 2.4  |
| 3           | CD74 HLA-class II histocompatibility antigen, DR invariant chain | Antigen presentation              | 2.2  |
| 4           | NPPB Natriuretic peptide B         | Neuropeptide hormone             | 2.1  |
| 5           | NPPA Natriuretic peptide A         | Neuropeptide hormone             | 2.1  |
| 6           | CD3D CD3 Delta Chain (CD3-TCR complex) | T-cell                  | 2.1  |
| 7           | CD8A Cluster of Differentiation 8A | Cytotoxic T-cell                | 1.8  |
| 8           | LUM Lumican                        | Extra-cellular matrix protein   | 1.7  |
| 9           | BGN Biglycan                       | Extra-cellular matrix binding   | 1.7  |
| 10          | COL6A2 Collagen alpha-2(VI) chain | Connective tissue               | 1.7  |
| 11          | FBLN2 Fibulin-2                    | Extra-cellular matrix protein   | 1.7  |
| 12          | EPHA3 Ephrin type-A receptor 3     | Protein-Tyrosine kinase         | 1.6  |
| 13          | AEBP1 Adipocyte enhancer-binding protein 1 precursor | Smooth muscle cell differentiation | 1.6  |
| 14          | SCD Stearoyl-CoA desaturase (delta-9-desaturase) | Fatty acid metabolism           | 1.6  |
| 15          | APOBEC3F DNA dC>dU-editing enzyme APOBEC-3F | Innate immune response | 1.6  |
| 16          | ECM1 Extra-cellular matrix protein 1 | Extra-cellular matrix protein    | 1.5  |
| 17          | UHFR1 Ubiquitin-like with PHD and ring finger | Chromatin structure regulation | 1.5  |
| 18          | WDR62 WD repeat-containing protein 62 | Cerebral cortical development    | -1.5 |
| 19          | STXBP6 Syntaxin binding protein (amisyn) | Exocytosis                      | -1.6 |
| 20          | APOD Apolipoprotein D              | Lipoprotein metabolism          | -1.7 |
| 21          | CSHL1 Chorionic somatomammotropin hormone-like 1 | Transcription regulator         | -1.8 |
| 22          | HMGCS2 3-hydroxy-3-methylglutaryl-CoA synthase 2 | Ketogenesis                    | -2.5 |

FC: Fold-change

doi:10.1371/journal.pone.0167213.t005

### Table 6. List of 11 annotated differentially expressed genes between C\(_{ISHLT}\) and BR\(_{ISHLT}\) groups.

| Gene symbol | Gene name                                      | Function                                      | FC  |
|-------------|-----------------------------------------------|-----------------------------------------------|-----|
| 1           | MAL Myelin and lymphocyte protein             | T-cell signal transduction                    | 1.5 |
| 2           | NR1D2 Nuclear Receptor Subfamily 1, Group D, Member 2 | Transcription regulator                      | 1.4 |
| 3           | C5ORF13 Neuronal regeneration related protein (= NREP) | Neuronal regeneration                        | 1.4 |
| 4           | TTN Titin                                      | Striated muscle contraction                  | 1.4 |
| 5           | TBX2 T-box 2                                   | Developmental processes regulation           | 1.4 |
| 6           | FRMD3 FERM Domain Containing 3                 | Tumor suppressor                              | 1.3 |
| 7           | F3 Coagulation factor III                      | Coagulation                                  | 1.3 |
| 8           | CDH13 Cadherin Heart 13                        | Cytoskeleton reorganization                   | 1.3 |
| 9           | SNCA Alpha-synuclein                           | Presynaptic signalling                        | -1.3|
| 10          | IFI6 Interferon alpha-inducible protein 6      | Apoptosis regulator                          | -1.3|
| 11          | PI16 Peptidase Inhibitor 16                    | Memory T regulator                           | -1.7|

FC: Fold-change

doi:10.1371/journal.pone.0167213.t006
Fig 4. Heatmap of gene expression with hierarchical clustering for the 15 probes differentially expressed between C\textsubscript{ISHLT} and BR\textsubscript{ISHLT} samples. Gene expressions row scaled.

doi:10.1371/journal.pone.0167213.g004

Fig 5. Representation of Linear discriminant analysis of C\textsubscript{ISHLT}, R\textsubscript{ISHLT} and BR\textsubscript{ISHLT} samples. Expression profiles were restricted to the set of 15 probes.

doi:10.1371/journal.pone.0167213.g005
we provide evidence that GEP changes might precede histological features. Moreover, the low number of genes differentially expressed before histological diagnosis of rejection, highlighting structural and immune modulations, allows to define a gene signature predicting ACR. Finally, using LDA, we show that this signature could be sufficient and of higher value for discriminating the three groups of EMB analyzed in this study.

**Molecular ACR signature**

The first part of our analysis highlighted a strong molecular immune activation during ACR that is consistent with the previously described pathophysiology of ACR.[13] Compared to other studies that explored gene expression in EMB, we found some identical immune pathways[8] such as the antigen presentation and dendritic cell maturation. Among genes differentially expressed with highest fold changes, were the CXCL9, interferon-gamma-inducible T-cell chemoattractant, and CCL5 (RANTES) that chemo-attracts and induces activation of T-cells and monocytes. Accordingly, these chemokines have been associated with allograft rejection. Urinary CXCL9 protein have been recently reported to have a strong predictive value for non-invasively diagnosing T cell-mediated kidney allograft rejection;[14] CCL5 have been described in cardiac allograft rejection, both in human[15–17] and animal models[18–20] where suppression of CCL5-mediated signals can alleviate transplant rejection severity. Interestingly, maraviroc, an antagonist of the CCL5 receptor CCR5 has been approved for clinical use in the treatment of HIV-infected patients,[21] and is investigated in graft-versus-host disease.[22] Hence, our results support the potential effects of maraviroc in the treatment of cardiac ACR, and provide targets for new therapeutic strategies.

Interestingly, none of the differentially-regulated genes identified in our study overlap with the gene panel used in the Allomap assay, the only test recommended for the non-invasive monitoring of ACR. However the Allomap assay is based on genes differentially expressed in the whole blood, which is probably very different from genes differentially expressed in the myocardium, as it has already been suggested.[6] Results from our study, focusing on myocardial GEP ability to predict and characterize ACR, and the IMAGE Study,[7] focusing on peripheral biomarkers of ACR, are thus not easily comparable.

**Molecular heterogeneity of severe ACR**

Interestingly, our results brought out the GEP heterogeneity among the RISHLT group: one sub-cluster was characterized by a strong immune activation and an interferon-mediated inflammatory state, while another was very close to the control group considering the fewer number of genes differentially expressed. This last sub-cluster was characterized by lower level of inflammation, an incipient cellular response, in addition to extracellular matrix changes that could be of great interest for clinical management. Besides, we found in this cluster an up-regulation of genes of natriuretic peptides ANP and BNP, currently used as biomarkers of heart disease.[23] Meirovich et al have already reported that BNP plasma levels were increased during a cardiac ACR episode grade 3A[24], promoted by pro-inflammatory and other cytokines including CCL5. Regarding the current results, natriuretic peptides up-regulation may be considered as reflect of myocardial stress preceding inflammatory signals during acute rejection. Given a good agreement between the two blind histological readings, heterogeneity in myocardial GEP among the rejection group appears to be unlikely due to miss-reads of the histological findings.

Taken together, these results indicate that GEP characterizes more in-depth molecular pattern of ACR than histopathology. Mengel[25] and Holweg[8] reported a discrepancy between the current ACR ISHLT histological grading system and the myocardial molecular profiles,
and also its lack of clinical relevance. This discrepancy and the associated lack of clinical relevance might thus be related to an insufficient sub-grading of ACR with pathological examination, highlighted by our results. Considering adverse effects of immunosuppressive therapies on one hand, and the decrease of the incidence of treated rejection during the past decade,[2] identifying ACR that need reinforced and/or targeted immunosuppressive therapy according to rejection stage is of crucial importance.

Cardiac molecular signs precede histological ACR alterations

In the second part of our study, we tested the ability of GEP analysis to identify, among samples without any history or current sign of ACR (grade 0), those evolving to rejection one month later. We demonstrated that mRNA expression pattern in EMB is modified one month before the histological rejection features. Among the 11 annotated genes differentially expressed, we found an up-regulation of TTN known to be the defining structural protein of the sarcomere. As a key element of myocardial passive tension, it is involved in the pathogenesis of heart disease, [26,27] and recently recognized as the major human disease gene for dilated cardiomyopathy.[28] We also found up-regulation of several collagen genes in the “intermediate” rejection sub-cluster, suggesting that early structural changes precede inflammatory response. Thus, up-regulation of TTN could be considered as an early marker of myocardial impairment. Further studies are needed to determine whether it is a non-immunological sign of rejection, or a “danger signal” leading to rejection. Besides, we found PI16 down-regulated in the BR\textsubscript{ISHLT} condition. Interestingly, the relative protein has been reported in cardiac muscle cell development [29] and also associated to functional memory regulatory T cells[30]. We can thus suggest that the under-expression of PI16 reduces its inflammatory regulation properties, and promotes ACR occurrence one month later.

Very few studies explored the potential of GEP in ACR prediction,[31,32] and they all used gene expression profiling score from Allomap test to distinguish patients with future rejection episode from those with persistent histologic quiescence. In contrast to the present study, none was specifically designed to explore, without any a priori notion, the specific molecular pattern of EMB before rejection. Thus, to our knowledge, the present results are the first to report that EMB, one month prior to an episode of ACR, presented a specific molecular pattern that can be used to distinguish them from long-term non-rejecting EMB. Applied to clinical settings, these results might guide actual protocol of EMB surveillance. Predicting immune event one month before might help starting specific treatment at an earlier stage, before occurrence of tissue damages.

Limitations

We acknowledge several limitations to this study. First the sample size was small, but consistent with what is usually done in GEP studies.[5,6,8] The reason is partly due to limited availability of EMB. Because of the small sample size, we were not able to perform subgroup analyzes and thus we did not assess the influence of confounding factors such as immune-suppressive therapy on changes in intragraft gene expression. However, age, gender, experimentation and sample conservation conditions were proved to behave as random in an ANOVA analysis. Second, we did not focus on antibody-mediated rejection (AMR) because none of the included patients did present AMR in their post-transplantation history, and there we are not able to confront our results to previous studies on endomyocardial biomarkers of AMR [33]. Lastly, gene expression results in our work are compared to the EMB pathological analysis, which is a poor gold standard, especially given the possible focal distribution of histological
lesions. Nevertheless we can expect the myocardial GEP distribution to be more homogeneous than histological lesions.

Conclusion and Perspectives

This study demonstrated that cardiac gene expression profiles matched partly the histological grading system, suggesting earlier and more sensitive performances in diagnosing ACR. Thus, cardiac GEP might provide an early screening test for ACR. Extension of this approach to peripheral blood and other types of rejection may be useful in clinical practice. Further large-scale studies are required to confirm the cardiac molecular signature of ACR in blood for developing a clinically accurate and non-invasive test to predict and diagnose acute cardiac allograft rejection.

Acknowledgments

Authors thank all the physicians of the Henri Mondor hospital who participated in the assessment and care of cardiac recipients included in this study.

Author Contributions

Conceptualization: DB HH LH TD.
Data curation: CB BG TD.
Formal analysis: DB NT TD.
Funding acquisition: JLDR YL TD.
Investigation: DB NB CB MK SG CR JPC ET.
Methodology: DB HH NT YL TD.
Project administration: BG JLDR YL TD.
Resources: JLDR ET YL TD.
Software: NT.
Supervision: YL TD.
Validation: DB PT NB.
Visualization: DB AG.
Writing – original draft: DB HH TD.
Writing – review & editing: DB AG YL TD.

References

1. Söderlund C, Rådegran G. Immunosuppressive therapies after heart transplantation—The balance between under- and over-immunosuppression. Transplant Rev Orlando Fla. 2015; 29: 181–189.
2. Lund LH, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dipchand AI, et al. The registry of the International Society for Heart and Lung Transplantation: thirty-first official adult heart transplant report—2014; focus theme: retransplantation. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2014; 33: 996–1008.
3. Stewart S, Winters GL, Fishbein MC, Tazelaar HD, Kobashigawa J, Abrams J, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2005; 24: 1710–1720.
4. Crespo-Leiro MG, Zuckermann A, Bara C, Mohacsi P, Schulz U, Boyle A, et al. Concordance among pathologists in the second Cardiac Allograft Rejection Gene Expression Observational Study (CARGO II). Transplantation. 2012; 94: 1172–1177. doi: 10.1097/TP.0b013e31826e19e2 PMID: 23222738

5. Horwitz PA, Tsai EJ, Putt ME, Gilmore JM, Lepore JJ, Parmacek MS, et al. Detection of cardiac allograft rejection and response to immunosuppressive therapy with peripheral blood gene expression. Circulation. 2004; 110: 3815–3821. doi: 10.1161/01.CIR.0000150539.72783.BF PMID: 15583081

6. Hollander Z, Lin D, Chen V, Ng R, Wilson-McManus J, Ignaszewski A, et al. Whole blood biomarkers of acute cardiac allograft rejection: double-crossing the biopsy. Transplantation. 2010; 90: 1388–1393. doi: 10.1097/TP.0b013e3182003d06 PMID: 21076371

7. Pham MX, Teuteberg JJ, Kfoury AG, Starling RC, Deng MC, Cappolla TP, et al. Gene-expression profiling for rejection surveillance after cardiac transplantation. N Engl J Med. 2010; 362: 1890–1900. doi: 10.1056/NEJMoa0912965 PMID: 20413602

8. Holweg CTJ, Potena L, Luikart H, Yu T, Berry GJ, Cooke JP, et al. Identification and classification of acute cardiac rejection by intragraft transcriptional profiling. Circulation. 2011; 123: 2236–2243. doi: 10.1161/CIRCULATIONAHA.109.913921 PMID: 21555702

9. Li L, Khush K, Hsieh S-C, Ying L, Luikart H, Sigdel T, et al. Identification of common blood gene signatures for the diagnosis of renal and cardiac allograft rejection. PloS One. 2013; 8: e82153. doi: 10.1371/journal.pone.0082153 PMID: 24358149

10. Khush KK, Pham MX, Teuteberg JJ, Kfoury AG, Deng MC, Kao A, et al. Gene expression profiling to study racial differences after heart transplantation. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2015; 34: 970–977.

11. Lassner D, Küh U, Siegismund CS, Rohde M, Elezkurtaj S, Escher F, et al. Improved diagnosis of idiopathic giant cell myocarditis and cardiac sarcoidosis by myocardial gene expression profiling. Eur Heart J. 2014; 35: 2186–2195. doi: 10.1093/euheartj/ehu101 PMID: 24667923

12. Smyth GK. Limma: linear models for microarray data. "Bioinformatics and Computational Biology Solutions using R and Bioconductor" R. Springer. New York: W. Huber; 2005. pp. 397–420.

13. Game DS, Lechler RI. Pathways of allorecognition: implications for transplantation tolerance. Transpl Immunol. 2002; 10: 101–108. PMID: 12216939

14. Hricik DE, Nickerson P, Formica RN, Poggio ED, Rush D, Newell KA, et al. Multicenter validation of urinary CXCL9 as a risk-stratifying biomarker for kidney transplant injury. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. 2013; 13: 2634–2644.

15. Azzawi M, Hasleton PS, Geraghty PJ, Yonan N, Krysiak P, El-Gammal A, et al. RANTES chemokine expression is related to acute cardiac cellular rejection and infiltration by CD45RO T-lymphocytes and macrophages. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 1998; 17: 881–887.

16. Michaels PJ, Kobashigawa J, Laks H, Azarbal A, Espejo ML, Chen L, et al. Differential expression of RANTES chemokine, TGF-beta, and leukocyte phenotype in acute cellular rejection and quilty B lesions. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2001; 20: 407–416.

17. Sigdel TK, Bestard O, Tran TQ, Hsieh S-C, Roedder S, Damm I, et al. A Computational Gene Expression Score for Predicting Immune Injury in Renal Allografts. PloS One. 2015; 10: e0138133. doi: 10.1371/journal.pone.0138133 PMID: 26367000

18. Mulligan MS, McDuffie JE, Shanley TP, Guo RF, Vidya Sarma J, Warner RL, et al. Role of RANTES in experimental cardiac allograft rejection. Exp Mol Pathol. 2000; 69: 167–174. doi: 10.1006/expm.2000.2327 PMID: 11115358

19. Vassalli G, Simeoni E, Li JP, Fleury S. Lentiviral gene transfer of the chemokine antagonist RANTES 9–68 prolongs heart graft survival. Transplantation. 2006; 81: 240–246. doi: 10.1097/01.tp.0000194859.98504.9e PMID: 16436968

20. Rosenblum JM, Shimoda N, Schenk AD, Zhang H, Kish DD, Keslar K, et al. CXC chemokine ligand (CXCL) 9 and CXCL10 are antagonistic costimulation molecules during the priming of alloreactive T cell effectors. J Immunol Baltim Md 1950. 2010; 184: 3450–3460.

21. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008; 359: 1429–1441. doi: 10.1056/NEJMoa0803152 PMID: 18832244

22. Reshef R, Luger SM, Hexner EO, Loren AW, Frey NV, Nasta SD, et al. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N Engl J Med. 2012; 367: 135–145. doi: 10.1056/NEJMoa1201248 PMID: 22784116

23. Song W, Wang H, Wu Q. Atrial natriuretic peptide in cardiovascular biology and disease (NPPA). Gene. 2015; 569: 1–6. doi: 10.1016/j.gene.2015.06.029 PMID: 26074089
24. Meirovich YF, Veinot JP, de Bold MLK, Haddad H, Davies RA, Masters RG, et al. Relationship between natriuretic peptides and inflammation: proteomic evidence obtained during acute cellular cardiac allograft rejection in humans. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2008; 27: 31–37.

25. Mengel M, Sis B, Kim D, Chang J, Famulski KS, Hidalgo LG, et al. The molecular phenotype of heart transplant biopsies: relationship to histopathological and clinical variables. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. 2010; 10: 2105–2115.

26. Nagueh SF, Shah G, Wu Y, Torre-Amione G, King NMP, Lahmers S, et al. Altered titin expression, myocardial stiffness, and left ventricular function in patients with dilated cardiomyopathy. Circulation. 2004; 110: 155–162. doi: 10.1161/01.CIR.0000135591.37759.AF PMID: 15238456

27. Hidalgo C, Granzier H. Tuning the molecular giant titin through phosphorylation: role in health and disease. Trends Cardiovasc Med. 2013; 23: 165–171. doi: 10.1016/j.tcm.2012.10.005 PMID: 23295080

28. Hinson JT, Chopra A, Nafissi N, Polacheck WJ, Benson CC, Swist S, et al. HEART DISEASE. Titin mutations in iPSC cells define sarcomere insufficiency as a cause of dilated cardiomyopathy. Science. 2015; 349: 982–986. doi: 10.1126/science.aaa5458 PMID: 26315439

29. Frost RJA, Engelhardt S. A secretion trap screen in yeast identifies protease inhibitor 16 as a novel anti-hypertrophic protein secreted from the heart. Circulation. 2007; 116: 1768–1775. doi: 10.1161/CIRCULATIONAHA.107.696468 PMID: 17909105

30. Nicholson IC, Mavrangezos C, Bird DRG, Bresat Atkinson S, Eastaff Leung NG, Grose RH, et al. PI16 is expressed by a subset of human memory Treg with enhanced migration to CCL17 and CCL20. Cell Immunol. 2012; 275: 12–18. doi: 10.1016/j.cellimm.2012.04.002 PMID: 22533972

31. Mehr Ra, Kobashigawa JA, Deng MC, Fang KC, Klangier TM, Lal PG, et al. Clinical implications and longitudinal alteration of peripheral blood transcriptional signals indicative of future cardiac allograft rejection. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2008; 27: 297–301.

32. Deng MC, Elashoff B, Pham MX, Teutec JJ, Kfoury AG, Starling RC, et al. Utility of gene expression profiling score variability to predict clinical events in heart transplant recipients. Transplantation. 2014; 97: 708–714. doi: 10.1097/01.TP.0000443897.29951.cf PMID: 24637869

33. Tible M, Loupy A, Vernerey D, Suberbielle C, Beuscart T, Cazes A, et al. Pathologic classification of antibody-mediated rejection correlates with donor-specific antibodies and endothelial cell activation. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2013; 32: 769–776.